BRPI0919881A2 - composições, métodos e usos para arcabouço com base no domínio fibronectina tipo iii - Google Patents

composições, métodos e usos para arcabouço com base no domínio fibronectina tipo iii

Info

Publication number
BRPI0919881A2
BRPI0919881A2 BRPI0919881A BRPI0919881A BRPI0919881A2 BR PI0919881 A2 BRPI0919881 A2 BR PI0919881A2 BR PI0919881 A BRPI0919881 A BR PI0919881A BR PI0919881 A BRPI0919881 A BR PI0919881A BR PI0919881 A2 BRPI0919881 A2 BR PI0919881A2
Authority
BR
Brazil
Prior art keywords
methods
type iii
domain type
fibronectin domain
framework compositions
Prior art date
Application number
BRPI0919881A
Other languages
English (en)
Inventor
Karyn T O'neil
Steven Jacobs
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of BRPI0919881A2 publication Critical patent/BRPI0919881A2/pt
Publication of BRPI0919881B1 publication Critical patent/BRPI0919881B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
BRPI0919881-4A 2008-10-31 2009-10-27 Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação BRPI0919881B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11012008P 2008-10-31 2008-10-31
US61/110,120 2008-10-31
PCT/US2009/062200 WO2010051274A2 (en) 2008-10-31 2009-10-27 Fibronectin type iii domain based scaffold compositions, methods and uses

Publications (2)

Publication Number Publication Date
BRPI0919881A2 true BRPI0919881A2 (pt) 2016-02-16
BRPI0919881B1 BRPI0919881B1 (pt) 2021-09-08

Family

ID=42129528

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919881-4A BRPI0919881B1 (pt) 2008-10-31 2009-10-27 Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação

Country Status (23)

Country Link
US (6) US8278419B2 (pt)
EP (2) EP2356269B1 (pt)
JP (3) JP5848607B2 (pt)
KR (1) KR101781907B1 (pt)
CN (1) CN102307896B (pt)
AU (3) AU2009308935B2 (pt)
BR (1) BRPI0919881B1 (pt)
CA (2) CA3149920A1 (pt)
CY (1) CY1118120T1 (pt)
DK (1) DK2356269T3 (pt)
EA (1) EA028304B1 (pt)
ES (2) ES2595504T3 (pt)
HR (1) HRP20161251T1 (pt)
HU (1) HUE030471T2 (pt)
IL (4) IL212531A (pt)
LT (1) LT2356269T (pt)
MX (1) MX2011004550A (pt)
PL (1) PL2356269T3 (pt)
PT (1) PT2356269T (pt)
RS (1) RS55218B1 (pt)
SI (1) SI2356269T1 (pt)
SM (1) SMT201600312B (pt)
WO (1) WO2010051274A2 (pt)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2552435A1 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
EP2121743B1 (en) 2006-11-22 2015-06-03 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
RU2010121967A (ru) 2007-10-31 2011-12-10 Медиммун, Ллк (Us) Белковые каркасные структуры
AU2009213141A1 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
EP2291399B1 (en) 2008-05-22 2014-06-25 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US8278419B2 (en) 2008-10-31 2012-10-02 Centocor Ortho Biotech Inc. Fibronectin type III domain based scaffold compositions, methods and uses
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
WO2010093627A2 (en) * 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
US20130079280A1 (en) 2010-04-13 2013-03-28 Medlmmune, Llc Fibronectin type iii domain-based multimeric scaffolds
AU2015271900B2 (en) * 2010-04-30 2017-02-02 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
BR112012027863B1 (pt) * 2010-04-30 2023-03-07 Janssen Biotech, Inc Polipeptídeos, arcabouços de proteína, bibliotecas e métodos de construção das mesmas, método para gerar uma ligação de arcabouço de proteína a um alvo específico com uma afinidade de ligação predefinida, moléculas de ácido nucleico isolada, vetores, células hospedeiras, composições, dispositivos médicos, e artigos de fabricação
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
JP6023703B2 (ja) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
US9096984B2 (en) 2010-12-07 2015-08-04 The Trustees Of Columbia University In The City Of New York Network material devices, methods, and systems
US8454980B2 (en) 2011-01-26 2013-06-04 Stanley William Whitson Hydrogel bioscaffold and coating for bone and tooth repair
EP3144320B9 (en) 2011-04-13 2018-08-22 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2012158678A1 (en) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
EP2710382B1 (en) 2011-05-17 2017-10-18 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
EP4151785A1 (en) * 2011-09-27 2023-03-22 Janssen Biotech, Inc. Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
WO2013055745A2 (en) 2011-10-11 2013-04-18 Medimmune, Llc Cd40l-specific tn3-derived scaffolds and methods of use thereof
WO2013067029A2 (en) 2011-10-31 2013-05-10 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
MX355041B (es) 2012-05-25 2018-03-28 Janssen Biotech Inc Dominios de union a albumina consenso no naturales.
PL2895503T3 (pl) 2012-09-13 2019-09-30 Bristol-Myers Squibb Company Oparte na fibronektynie białka z domeną rusztowania, które wiążą się z miostatyną
HUE041499T2 (hu) 2012-11-21 2019-05-28 Janssen Biotech Inc Bispecifikus EGFR/C-MET-ellenanyagok
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
WO2014124017A1 (en) 2013-02-06 2014-08-14 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
EP3299378B1 (en) 2013-02-12 2019-07-31 Bristol-Myers Squibb Company High ph protein refolding methods
US10183967B2 (en) 2013-02-12 2019-01-22 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
JP6423804B2 (ja) 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤を含む複合体
EP3566750A3 (en) 2013-02-28 2020-04-08 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US20160152686A1 (en) 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US10196446B2 (en) * 2013-10-14 2019-02-05 Janssen Biotech, Inc. Cysteine engineered fibronectin type III domain binding molecules
KR20160097294A (ko) 2013-12-09 2016-08-17 뉴욕 유니버시티 항-포도상구균 제제의 식세포 전달을 위한 조성물 및 방법
KR20220162886A (ko) 2014-03-20 2022-12-08 브리스톨-마이어스 스큅 컴퍼니 혈청 알부민-결합 피브로넥틴 유형 iii 도메인
WO2015143156A1 (en) 2014-03-20 2015-09-24 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
EP3189057A1 (en) 2014-09-03 2017-07-12 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
CA2959630A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
WO2016049367A1 (en) * 2014-09-24 2016-03-31 Los Alamos National Security, Llc Multi-organ media compositions and methods of their use
WO2016086036A2 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of biologics
EP3842451A1 (en) 2015-03-12 2021-06-30 MedImmune, LLC Method of purifying albumin-fusion proteins
JP6894846B2 (ja) * 2015-04-24 2021-06-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド Ｈｉｖ融合体を標的とするポリペプチド
EP3291836A4 (en) 2015-05-06 2018-11-14 Janssen Biotech, Inc. Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
BR112017023798A2 (pt) * 2015-05-06 2018-10-16 Janssen Biotech Inc domínios fibronectina tipo iii de ligação a antígeno prostático específico de membrana
HRP20231392T1 (hr) 2015-05-15 2024-04-26 The General Hospital Corporation Antagonistička protutijela na superobitelj receptora za faktor tumorske nekroze
EP3302532A4 (en) 2015-06-05 2019-01-09 New York University COMPOSITIONS AND METHODS RELATED TO ANTISTAPHYLOCOCCAL BIOLOGICAL AGENTS
CN108350076B (zh) 2015-08-17 2022-06-07 詹森药业有限公司 抗-bcma抗体，结合bcma和cd3的双特异性抗原结合分子及其用途
WO2017048709A1 (en) 2015-09-14 2017-03-23 Arizona Board Of Regents On Behalf Of Arizona State University Generating recominant affinity reagents with arrayed targets
EP3708580B1 (en) 2015-09-23 2023-11-01 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains
KR20180072820A (ko) 2015-11-02 2018-06-29 얀센 파마슈티카 엔.브이. 항-il1rap 항체, il1rap 및 cd3과 결합하는 이중특이성 항원 결합 분자, 및 그의 용도
EP3450556B1 (en) * 2016-04-27 2022-03-23 Osaka University Peptide inhibiting colonization by pathogenic bacteria, and colonization inhibitor including same
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
SG11201810687SA (en) * 2016-06-03 2018-12-28 Janssen Biotech Inc Serum albumin-binding fibronectin type iii domains
EA201990067A1 (ru) 2016-06-21 2019-07-31 Янссен Байотек, Инк. Цистеин-модифицированные связывающие молекулы на основе домена фибронектина iii типа
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
KR20190046854A (ko) 2016-09-14 2019-05-07 얀센 바이오테크 인코포레이티드 Bcma-특이적 피브로넥틴 iii 형 도메인을 포함하는 키메라 항원 수용체 및 그의 용도
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
EP3932432A1 (en) * 2016-12-14 2022-01-05 Janssen Biotech, Inc. Cd8a-binding fibronectin type iii domains
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
RU2765098C2 (ru) 2017-02-28 2022-01-25 Иммуноджен, Инк. Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
KR20200028447A (ko) 2017-07-17 2020-03-16 얀센 바이오테크 인코포레이티드 피브로넥틴 iii형 도메인에 대한 항원 결합 영역 및 이의 사용 방법
EP3672611A4 (en) 2017-08-25 2021-07-14 Janssen Biotech, Inc. TYPE III DOMAINS OF FIBRONECTIN BINDER FCyRII, THEIR CONJUGATES AND MULTISPECIFIC MOLECULES INCLUDING THEM
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
TWI827575B (zh) 2017-12-28 2024-01-01 美商伊繆諾金公司 苯二氮平衍生物
CN110276503B (zh) * 2018-03-14 2023-04-21 吉旗物联科技（上海）有限公司 一种自动识别冷链车辆任务的方法
KR101995774B1 (ko) * 2018-05-08 2019-07-03 한국세라믹기술원 뎅기열 바이러스에 특이적으로 결합하는 피브로넥틴 edb 단백질 스캐폴드
KR20210011002A (ko) 2018-05-16 2021-01-29 얀센 바이오테크 인코포레이티드 암을 치료하는 방법 및 t-세포 재유도 치료제의 효능을 향상시키는 방법
CN113573729A (zh) 2019-01-10 2021-10-29 詹森生物科技公司 前列腺新抗原及其用途
US11833214B2 (en) 2019-03-21 2023-12-05 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
TW202102506A (zh) 2019-03-29 2021-01-16 美商伊繆諾金公司 苯二氮平衍生物
CN113766954B (zh) 2019-04-26 2024-09-24 伊缪诺金公司 喜树碱衍生物
CN114401987A (zh) 2019-07-12 2022-04-26 詹森药业有限公司 结合剂及其用途
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
WO2021076546A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
IL293051A (en) 2019-11-18 2022-07-01 Janssen Biotech Inc calr and jak2 mutant-based vaccines and their uses
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
JP2023515633A (ja) 2020-02-28 2023-04-13 ブリストル－マイヤーズ スクイブ カンパニー 放射性標識されたフィブロネクチンに基づく足場および抗体ならびにそのセラノスティクス的使用
US20210315973A1 (en) * 2020-04-08 2021-10-14 Nostrum Pharmaceuticals, Llc Compositions and methods using interferon for treating viral respiratory infections
BR112022022800A2 (pt) 2020-05-11 2022-12-13 Janssen Biotech Inc Métodos para tratamento de mieloma múltiplo
AU2021377232A1 (en) 2020-11-10 2023-06-15 New York University Macropinocytosis selective monobody-drug conjugates
WO2022175255A2 (en) 2021-02-16 2022-08-25 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
US11639396B2 (en) 2021-02-16 2023-05-02 Janssen Biotech, Inc. Antibody binding to a linker peptide
EP4314070A1 (en) 2021-03-24 2024-02-07 Janssen Biotech, Inc. Trispecific antibody targeting cd79b, cd20, and cd3
WO2022201053A1 (en) 2021-03-24 2022-09-29 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
JP2024512035A (ja) 2021-03-24 2024-03-18 ヤンセン バイオテツク，インコーポレーテツド Ｃｄ２２及びｃｄ７９ｂを標的とする抗体
MX2023012128A (es) 2021-04-14 2024-01-11 Aro Biotherapeutics Company Dominios tipo iii de la fibronectina que se unen a cd71.
AU2022380722A1 (en) 2021-11-03 2024-06-20 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2374910A1 (fr) 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US4939666A (en) 1987-09-02 1990-07-03 Genex Corporation Incremental macromolecule construction methods
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2084307A1 (en) 1990-06-01 1991-12-02 Cetus Oncology Corporation Compositions and methods for identifying biologically active molecules
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
EP0572529A4 (en) 1991-02-21 1994-11-02 Gilead Sciences Inc SPECIFIC APTAMER OF BIOMOLECULES AND PROCESS FOR PRODUCING THE SAME.
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
SG47099A1 (en) 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
JP3230056B2 (ja) 1991-07-02 2001-11-19 インヘイル・インコーポレーテッド 薬剤のエーロゾル化服用量を形成する装置
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
ES2313867T3 (es) 1991-12-02 2009-03-16 Medical Research Council Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos.
WO1994006498A1 (en) 1992-09-23 1994-03-31 Fisons Plc Inhalation device
HU217917B (hu) 1992-10-19 2000-05-28 Dura Pharmaceuticals Inc. Inhalálókészülék száraz porok inhalálásához
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
EP0680451B1 (en) 1993-01-19 1998-11-04 Glaxo Group Limited Aerosol dispenser and method of manufacture
ATE300617T1 (de) * 1993-02-05 2005-08-15 Smithkline Beecham Plc Fibronektinbindungsprotein, monoklonaler antikoerper und ihre verwendung zur verhuetung der adhäsion von bakterien
WO1994018317A1 (en) 1993-02-12 1994-08-18 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5549551A (en) 1994-12-22 1996-08-27 Advanced Cardiovascular Systems, Inc. Adjustable length balloon catheter
GB9524630D0 (en) * 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
JP2000503565A (ja) 1996-01-03 2000-03-28 グラクソ、グループ、リミテッド 吸入装置
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
WO1999014318A1 (en) 1997-09-16 1999-03-25 Board Of Regents, The University Of Texas System Method for the complete chemical synthesis and assembly of genes and genomes
IL135126A0 (en) 1997-09-29 2001-05-20 Inhale Therapeutic Syst Perforated microparticles and methods of use and preparation thereof
US6846655B1 (en) 1998-06-29 2005-01-25 Phylos, Inc. Methods for generating highly diverse libraries
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ATE439592T1 (de) 1998-12-10 2009-08-15 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
US7115396B2 (en) * 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
JP4578768B2 (ja) * 2000-07-11 2010-11-10 リサーチ コーポレイション テクノロジーズ，インコーポレイテッド 人工抗体ポリペプチド
AU2002213251B2 (en) 2000-10-16 2007-06-14 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
GB0119476D0 (en) * 2001-08-09 2001-10-03 Novartis Forschungsstiftlung Z Anti-tumour agents and method of identifying anti-tumour agents
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
CA2497496C (en) 2002-09-06 2012-05-15 Isogenica Limited In vitro peptide expression library
WO2004029224A2 (en) 2002-09-30 2004-04-08 Compound Therapeutics, Inc. Methods of engineering spatially conserved motifs in polypeptides
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2005056754A2 (en) 2003-11-19 2005-06-23 The Scripps Research Institute Compositions and methods to reduce mutagenesis
CA2552435A1 (en) * 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
US20060040278A1 (en) * 2004-01-27 2006-02-23 Cojocaru Gad S Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer
WO2007085815A2 (en) 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
TW200745556A (en) * 2006-01-24 2007-12-16 Ind Tech Res Inst Biomarkers for liver fibrotic injury
US8536113B2 (en) 2006-12-21 2013-09-17 Janssen Biotech, Inc. EGFR binding peptides and uses thereof
WO2008156642A1 (en) 2007-06-15 2008-12-24 Vasgene Therapeutics, Inc. Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth
JP5781762B2 (ja) 2007-08-10 2015-09-24 プロテリックス、インク ユニバーサルｉｉｉ型フィブロネクチン結合ドメインのライブラリ
RU2010121967A (ru) 2007-10-31 2011-12-10 Медиммун, Ллк (Us) Белковые каркасные структуры
CA2709994A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Non-antibody scaffold protein fusions phage display via fusion to pix of m13 phage
EP2274331B1 (en) 2008-05-02 2013-11-06 Novartis AG Improved fibronectin-based binding molecules and uses thereof
US8278419B2 (en) 2008-10-31 2012-10-02 Centocor Ortho Biotech Inc. Fibronectin type III domain based scaffold compositions, methods and uses
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
WO2010093627A2 (en) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
EP2452165A1 (en) 2009-07-07 2012-05-16 Siemens AG Apparatus and method for measuring multi-phase fluid flow
BR112012027863B1 (pt) 2010-04-30 2023-03-07 Janssen Biotech, Inc Polipeptídeos, arcabouços de proteína, bibliotecas e métodos de construção das mesmas, método para gerar uma ligação de arcabouço de proteína a um alvo específico com uma afinidade de ligação predefinida, moléculas de ácido nucleico isolada, vetores, células hospedeiras, composições, dispositivos médicos, e artigos de fabricação
CN103403027A (zh) 2010-07-30 2013-11-20 诺华有限公司 纤连蛋白摇篮分子和其库

Also Published As

Publication number Publication date
IL212531A0 (en) 2011-06-30
US11479880B2 (en) 2022-10-25
JP5848607B2 (ja) 2016-01-27
LT2356269T (lt) 2016-09-12
IL232095A0 (en) 2014-05-28
CN102307896B (zh) 2016-10-12
CA3149920A1 (en) 2010-05-06
US20160039909A1 (en) 2016-02-11
ES2705714T3 (es) 2019-03-26
ES2595504T3 (es) 2016-12-30
BRPI0919881B1 (pt) 2021-09-08
AU2009308935B2 (en) 2015-02-26
EP2356269A2 (en) 2011-08-17
CY1118120T1 (el) 2017-06-28
KR20110079912A (ko) 2011-07-11
EP3128048B1 (en) 2018-11-28
US9200059B2 (en) 2015-12-01
WO2010051274A3 (en) 2010-09-10
US20200291094A1 (en) 2020-09-17
IL212531A (en) 2016-07-31
PT2356269T (pt) 2016-09-13
EP2356269B1 (en) 2016-06-29
CN102307896A (zh) 2012-01-04
SI2356269T1 (sl) 2016-10-28
EP2356269A4 (en) 2013-01-09
US8278419B2 (en) 2012-10-02
WO2010051274A2 (en) 2010-05-06
IL232094A (en) 2017-05-29
CA2741834C (en) 2022-04-05
DK2356269T3 (en) 2016-08-15
US20180334492A1 (en) 2018-11-22
AU2015202864A1 (en) 2015-06-18
US20100216708A1 (en) 2010-08-26
JP6124267B2 (ja) 2017-05-10
MX2011004550A (es) 2011-07-20
AU2017236012A1 (en) 2017-10-26
KR101781907B1 (ko) 2017-09-26
EA028304B1 (ru) 2017-11-30
JP6599394B2 (ja) 2019-10-30
SMT201600312B (it) 2016-11-10
AU2009308935A1 (en) 2010-05-06
EA201170635A1 (ru) 2011-12-30
PL2356269T3 (pl) 2016-12-30
JP2012507295A (ja) 2012-03-29
JP2017141265A (ja) 2017-08-17
JP2015205897A (ja) 2015-11-19
US10040842B2 (en) 2018-08-07
US10654913B2 (en) 2020-05-19
US20230071749A1 (en) 2023-03-09
IL232095A (en) 2017-05-29
IL232094A0 (en) 2014-05-28
US20130096019A1 (en) 2013-04-18
RS55218B1 (sr) 2017-02-28
HUE030471T2 (en) 2017-05-29
CA2741834A1 (en) 2010-05-06
EP3128048A1 (en) 2017-02-08
HRP20161251T1 (hr) 2016-11-18
IL232093A0 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
BRPI0919881A2 (pt) composições, métodos e usos para arcabouço com base no domínio fibronectina tipo iii
BRPI1008532A2 (pt) "composições, métodos e usos para arcabouço com base no domínio fibronectina tipo iii".
DK3569256T3 (da) Stabiliserede fibronectin-domænesammensætninger, fremgangsmåder og anvendelser
BRPI1008709A2 (pt) composições e usos das mesmas.
DK2638807T3 (da) Drikkevaresammensætninger
BRPI0822337A2 (pt) Folatos, composições e usos dos mesmos
BRPI0910378A2 (pt) composições imunogênicas anti-amilóides, métodos e usos
BRPI0910476A2 (pt) composições de vacinas para tratamento de febre do dengue e seus usos
FR2943252B1 (fr) Composition dermo-cosmetique
TH100135B (th) เก้าอี้นักเรียน
UA17812S (uk) Табурет
ES1067177Y (es) Soporte para bebidas
TH119056B (th) จานรองแก้ว
ES1069058Y (es) Entarimado para exteriores
TH117056B (th) เก้าอี้
TH111883B (th) เก้าอี้
TH100454B (th) เก้าอี้
TH100455B (th) เก้าอี้
TH102224B (th) เก้าอี้
TH102621B (th) เก้าอี้
TH103342B (th) เก้าอี้
TH104539B (th) เก้าอี้
TH104628B (th) เก้าอี้
TH106412B (th) เก้าอี้
TH106413B (th) เก้าอี้

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.